345 related articles for article (PubMed ID: 24977963)
21. First series of 18 pregnancies after ulipristal acetate treatment for uterine fibroids.
Luyckx M; Squifflet JL; Jadoul P; Votino R; Dolmans MM; Donnez J
Fertil Steril; 2014 Nov; 102(5):1404-9. PubMed ID: 25241376
[TBL] [Abstract][Full Text] [Related]
22. The history and use of the progesterone receptor modulator ulipristal acetate for heavy menstrual bleeding with uterine fibroids.
Bouchard P; Chabbert-Buffet N
Best Pract Res Clin Obstet Gynaecol; 2017 Apr; 40():105-110. PubMed ID: 28169130
[TBL] [Abstract][Full Text] [Related]
23. Current management of myomas: the place of medical therapy with the advent of selective progesterone receptor modulators.
Donnez J; Arriagada P; Donnez O; Dolmans MM
Curr Opin Obstet Gynecol; 2015 Dec; 27(6):422-31. PubMed ID: 26536207
[TBL] [Abstract][Full Text] [Related]
24. Ulipristal acetate modulates the expression and functions of activin a in leiomyoma cells.
Ciarmela P; Carrarelli P; Islam MS; Janjusevic M; Zupi E; Tosti C; Castellucci M; Petraglia F
Reprod Sci; 2014 Sep; 21(9):1120-5. PubMed ID: 25001022
[TBL] [Abstract][Full Text] [Related]
25. Outcome of patients with uterine fibroids after 3-month ulipristal acetate therapy.
Brun JL; Rajaonarison J; Froeliger A; Monseau-Thiburce AC; Randriamboavonjy R; Vogler A
Eur J Obstet Gynecol Reprod Biol; 2018 Mar; 222():13-18. PubMed ID: 29328939
[TBL] [Abstract][Full Text] [Related]
26. Ulipristal acetate: a novel option for the medical management of symptomatic uterine fibroids.
Talaulikar VS; Manyonda IT
Adv Ther; 2012 Aug; 29(8):655-63. PubMed ID: 22903240
[TBL] [Abstract][Full Text] [Related]
27. The clinical pharmacology and pharmacokinetics of ulipristal acetate for the treatment of uterine fibroids.
Pohl O; Zobrist RH; Gotteland JP
Reprod Sci; 2015 Apr; 22(4):476-83. PubMed ID: 25228633
[TBL] [Abstract][Full Text] [Related]
28. Ulipristal Acetate: A Review in Symptomatic Uterine Fibroids.
Garnock-Jones KP; Duggan ST
Drugs; 2017 Oct; 77(15):1665-1675. PubMed ID: 28900897
[TBL] [Abstract][Full Text] [Related]
29. [The molecular mechanisms and morphological manifestations of leiomyoma reduction induced by selective progesterone receptor modulators].
Demura TA; Revazova ZV; Kogan EA; Adamyan LV
Arkh Patol; 2017; 79(3):19-26. PubMed ID: 28631712
[TBL] [Abstract][Full Text] [Related]
30. Emerging treatment options for uterine fibroids.
Donnez J; Arriagada P; Donnez O; Dolmans MM
Expert Opin Emerg Drugs; 2018 Mar; 23(1):17-23. PubMed ID: 29486606
[TBL] [Abstract][Full Text] [Related]
31. Ulipristal acetate decreases transforming growth factor β3 serum and tumor tissue concentrations in patients with uterine fibroids.
Ciebiera M; Włodarczyk M; Wrzosek M; Słabuszewska-Jóźwiak A; Nowicka G; Jakiel G
Fertil Steril; 2018 Mar; 109(3):501-507.e2. PubMed ID: 29525690
[TBL] [Abstract][Full Text] [Related]
32. Use of Ulipristal Acetate for the Management of Fibroid-Related Acute Abnormal Uterine Bleeding.
Arendas K; Leyland NA
J Obstet Gynaecol Can; 2016 Jan; 38(1):80-3. PubMed ID: 26872761
[TBL] [Abstract][Full Text] [Related]
33. Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate.
Williams AR; Bergeron C; Barlow DH; Ferenczy A
Int J Gynecol Pathol; 2012 Nov; 31(6):556-69. PubMed ID: 23018219
[TBL] [Abstract][Full Text] [Related]
34. Ulipristal acetate: in uterine fibroids.
Croxtall JD
Drugs; 2012 May; 72(8):1075-85. PubMed ID: 22568731
[TBL] [Abstract][Full Text] [Related]
35. The cost-effectiveness of ulipristal acetate tablets in treating patients with moderate to severe symptoms of uterine fibroids.
Nagy B; Timár G; Józwiak-Hagymásy J; Kovács G; Merész G; Vámossy I; Ágh T; László Á; Vokó Z; Kaló Z
Eur J Obstet Gynecol Reprod Biol; 2014 Apr; 175():75-81. PubMed ID: 24568866
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic drugs in the treatment of symptomatic uterine fibroids.
Hoellen F; Griesinger G; Bohlmann MK
Expert Opin Pharmacother; 2013 Oct; 14(15):2079-85. PubMed ID: 23914973
[TBL] [Abstract][Full Text] [Related]
37. Vilaprisan for treating uterine fibroids.
Melis GB; Neri M; Piras B; Paoletti AM; Ajossa S; Pilloni M; Marotto MF; Corda V; Saba A; Giancane E; Mais V
Expert Opin Investig Drugs; 2018 May; 27(5):497-505. PubMed ID: 29718788
[TBL] [Abstract][Full Text] [Related]
38. Safety after extended repeated use of ulipristal acetate for uterine fibroids.
Fauser BC; Donnez J; Bouchard P; Barlow DH; Vázquez F; Arriagada P; Skouby SO; Palacios S; Tomaszewski J; Lemieszczuk B; William AR
PLoS One; 2017; 12(3):e0173523. PubMed ID: 28267814
[TBL] [Abstract][Full Text] [Related]
39. The use of selective progestin receptor modulators (SPRMs) and more specifically ulipristal acetate in the practice of gynaecology.
Rozenberg S; Praet J; Pazzaglia E; Gilles C; Manigart Y; Vandromme J
Aust N Z J Obstet Gynaecol; 2017 Aug; 57(4):393-399. PubMed ID: 28567743
[TBL] [Abstract][Full Text] [Related]
40. Endometrial Effects of Prolonged Therapy with the Selective Progesterone Receptor Modulator Ulipristal Acetate: A Case Report.
Levy G; Elkas J; Armstrong AY; Nieman LK
J Reprod Med; 2016; 61(3-4):159-62. PubMed ID: 27172639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]